| P2093 | author name string | Anas Younes | |
| | Victor Yazbeck | |
| | Georgios V Georgakis | |
| | Amanda Wedgwood | |
| P2860 | cites work | Phosphorylation of the PTEN tail regulates protein stability and function | Q22254305 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF | Q24316162 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Modulation of Akt kinase activity by binding to Hsp90 | Q24648565 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer | Q24681630 |
| | Potential for proteasome inhibition in the treatment of cancer | Q28186033 |
| | MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival | Q28190315 |
| | Direct identification of PTEN phosphorylation sites | Q28203697 |
| | Mammalian MAP kinase signalling cascades | Q28204140 |
| | Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival | Q28205125 |
| | Clinical development of histone deacetylase inhibitors as anticancer agents | Q28244438 |
| | Inhibition of Hsp90: a new strategy for inhibiting protein kinases | Q28250656 |
| | ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi | Q28273184 |
| | Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report | Q28287838 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death | Q40385936 |
| | The B7 and CD28 receptor families | Q40392461 |
| | Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma | Q40402220 |
| | Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. | Q40406947 |
| | Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor | Q40408470 |
| | Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. | Q40457592 |
| | Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors | Q40558321 |
| | Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications | Q40566183 |
| | Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. | Q40568050 |
| | Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group | Q40568223 |
| | A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors | Q40631570 |
| | Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation | Q40723275 |
| | Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. | Q40761212 |
| | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | Q40772885 |
| | Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. | Q40781126 |
| | Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells | Q40809076 |
| | CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. | Q40810972 |
| | Beta1-integrin and PTEN control the phosphorylation of protein kinase C. | Q40841368 |
| | Reed-Sternberg cells and the TNF family of receptors/ligands | Q40875592 |
| | CD30 ligand in lymphoma patients with CD30+ tumors | Q41080251 |
| | B7-mediated costimulation and the immune response | Q41116012 |
| | B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease | Q41137287 |
| | Rare occurrence of classical Hodgkin's disease as a T cell lymphoma | Q41811025 |
| | Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase | Q43842315 |
| | CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome | Q43899633 |
| | BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective | Q44372692 |
| | Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation | Q44470180 |
| | Involved-field radiotherapy for advanced Hodgkin's lymphoma. | Q44475165 |
| | High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. | Q44477265 |
| | Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma | Q45242163 |
| | Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells | Q45299110 |
| | Serum levels of soluble CD30 in chronic hepatitis B virus infection | Q45772022 |
| | Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors | Q46065988 |
| | The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. | Q46128923 |
| | Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group | Q46443817 |
| | Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). | Q46825132 |
| | Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death | Q46905283 |
| | Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma | Q46930684 |
| | A pilot study of rituximab in patients with recurrent, classic Hodgkin disease | Q47748021 |
| | Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. | Q50760142 |
| | Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. | Q51024704 |
| | Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. | Q52958016 |
| | Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma | Q56903494 |
| | Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma | Q57631157 |
| | Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays | Q57631186 |
| | Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions | Q29547189 |
| | The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 |
| | NF-kappaB at the crossroads of life and death | Q29619302 |
| | Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma | Q30660853 |
| | A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model | Q31828046 |
| | Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. | Q33193186 |
| | Histone deacetylase inhibitors | Q33210740 |
| | Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation | Q33236181 |
| | Apoptotic and autophagic cell death induced by histone deacetylase inhibitors | Q33583208 |
| | Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death | Q33696062 |
| | The molecular and cellular origins of Hodgkin's disease | Q33818404 |
| | Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy | Q33841251 |
| | The role of chemokines in Hodgkin's disease | Q33929840 |
| | Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo | Q33942901 |
| | Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex | Q34101673 |
| | Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. | Q34131747 |
| | CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies | Q34266298 |
| | Heat-shock proteins as regulators of apoptosis | Q34282224 |
| | HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. | Q34403841 |
| | Engineered antibody Fc variants with enhanced effector function | Q34424958 |
| | Rational development of histone deacetylase inhibitors as anticancer agents: a review | Q34426444 |
| | Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. | Q34467657 |
| | A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease | Q34480381 |
| | Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial | Q34524632 |
| | Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease | Q34534439 |
| | ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results | Q34548681 |
| | Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease | Q34550216 |
| | The Hodgkin and Reed/Sternberg cell | Q34553716 |
| | The role of cytokines in classical Hodgkin lymphoma | Q34661066 |
| | Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease | Q34700710 |
| | Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial | Q34726922 |
| | Targeting death and decoy receptors of the tumour-necrosis factor superfamily | Q34791120 |
| | BAFF AND APRIL: a tutorial on B cell survival | Q34994661 |
| | How the ubiquitin-proteasome system controls transcription | Q35075758 |
| | BAFF and the regulation of B cell survival | Q35174478 |
| | Nuclear transcription factor-kappaB in Hodgkin's disease | Q35175282 |
| | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders | Q35184335 |
| | Survival and proliferation factors of normal and malignant plasma cells | Q35211028 |
| | The uncertain glory of APRIL. | Q35540065 |
| | Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. | Q35564020 |
| | Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease | Q35570304 |
| | Targeting the PI3K-Akt pathway in human cancer: rationale and promise | Q35571372 |
| | Clinicopathologic and Molecular Features of Hodgkin Lymphoma | Q35582355 |
| | Heat shock protein 90. | Q35587293 |
| | Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. | Q35610634 |
| | Part II: Hodgkin's lymphoma--diagnosis and treatment | Q35618783 |
| | PI3K/Akt signalling pathway and cancer. | Q35692250 |
| | Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 |
| | The development of proteasome inhibitors as anticancer drugs | Q35773857 |
| | Therapeutic and diagnostic implications of Hsp90 activation | Q35791991 |
| | PI3K signaling controls cell fate at many points in B lymphocyte development and activation | Q35812420 |
| | Hsp90: an emerging target for breast cancer therapy | Q35843175 |
| | Histone deacetylase inhibitors open new doors in cancer therapy | Q35864048 |
| | Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development | Q35888216 |
| | Hsp90: the vulnerable chaperone | Q35913771 |
| | Hsp90 activation and cell cycle regulation | Q35946757 |
| | Histone deacetylase inhibitors and cancer: from cell biology to the clinic | Q36093171 |
| | ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do? | Q36179868 |
| | Molecular pathogenesis of Hodgkin's lymphoma | Q36254637 |
| | State-of-the-art therapeutics: Hodgkin's lymphoma | Q36254651 |
| | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 |
| | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease | Q36399791 |
| | Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond | Q36429460 |
| | BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone | Q36663554 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling | Q39741184 |
| | Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells | Q39795545 |
| | cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. | Q40347662 |
| | Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma | Q40348386 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 533-551 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Hodgkin's lymphoma: molecular targets and novel treatment strategies | |
| P478 | volume | 2 | |